AbbVie Inc. (ABBV) fair value analysis

S&P 500 · Updated 2026-09-07

AbbVie Inc. is a biopharmaceutical company that discovers, develops, manufactures, and markets a broad range of pharmaceutical products, including treatments for immunology, oncology, virology, and other therapeutic areas. The company operates globally with a significant presence in North America, Europe, and international markets.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, ABBV is trading at within about 10% of estimated fair value.

ABBV currently ranks #83 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $256.46
Sector: Healthcare
12-month range: $206.60–$259.99

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Fairly Valued

What our data shows for ABBV

Our model validated 17 trailing price-to-earnings windows for ABBV, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $206.60–$259.99.
The 14-day relative strength index sits at a neutral 55.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ABBV
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ABBV news

TickrTrends' derived news-sentiment signal for ABBV is currently leaning positive, computed from recent coverage.

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) (finance.yahoo.com, 2026-09-05)
TickrTrends take: AbbVie is included in a discussion of dividend stocks positioned for long-term holding, which aligns with the company's established track record as a mature healthcare business generating consistent returns to shareholders. Given TickrTrends' assessment that ABBV is fairly valued, investors focused on valuation metrics should monitor whether the dividend yield remains attractive relative to peers in the Healthcare sector and whether earnings growth can sustain the dividend over time. For those considering ABBV as a hold-forever position, tracking the company's ability to maintain pricing power and manage its cost structure will be important indicators of whether fair value holds or shifts.
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story (insidermonkey.com, 2026-09-04)
TickrTrends take: AbbVie's advancement in blood cancer treatments strengthens the fundamental case for its pipeline, which represents a significant component of how the company might sustain revenue growth beyond its current product portfolio. With TickrTrends assessing the stock as fairly valued, investors tracking the Healthcare sector should monitor whether clinical or commercial progress in oncology translates into earnings revisions that could shift the valuation assessment. The pipeline's success or setbacks will be critical to determining whether ABBV's current valuation adequately reflects the company's medium and long-term growth prospects.
Top Analyst Reports for Amazon, AbbVie & Alibaba (zacks.com, 2026-09-03)
TickrTrends take: AbbVie appears in analyst coverage alongside major technology and e-commerce companies, suggesting the stock receives attention comparable to high-profile names despite operating in the Healthcare sector. Given TickrTrends' current assessment of the stock as fairly valued, investors monitoring analyst reports should consider whether recent commentary reflects factors that might shift this valuation view or affirm the current positioning. The concentration of analyst attention on ABBV warrants tracking whether any consensus shifts emerge that could challenge its fairly valued status.

What people are saying

Follow the ABBV conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # ABBV - TickrTrends Weekly Summary ABBV's valuation assessment shifted this week as the DCF cross-check band moved from undervalued to fairly valued, aligning with the current overall valuation verdict of fairly valued. This adjustment reflects changes in the underlying financial metrics or market conditions tracked by TickrTrends' derived indicators for the healthcare sector company.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ABBV stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ABBV is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is ABBV's TickrTrends verdict?

ABBV's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does ABBV compare to other Healthcare stocks?

ABBV ranks #83 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ABBV overbought or oversold?

ABBV's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ABBV vs BIIB · ABBV vs BIO · ABBV vs BVS · ABBV vs HCSG · ABBV vs JAZZ